Bristol-Myers Squibb: Breast Neoplasms trials

The registry lists 44 Breast Neoplasms studies with Bristol-Myers Squibb as lead sponsor. 4 are open to participants now and 20 have results posted.

Early Phase 1 1Phase 1 13Phase 2 31Phase 3 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLCRecruitingNCT07671092Early Phase 1
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)RecruitingNCT06926868Phase 2/3
• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsRecruitingNCT06618287Phase 1/2
• Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.RecruitingNCT06590857Phase 1/2
• Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerCompletedNCT04109066Phase 3Results posted
• A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast CancerCompletedNCT04075604Phase 2Results posted
• Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With FulvestrantTerminatedNCT02374099Phase 2Results posted
• Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)CompletedNCT01881230Phase 2/3Results posted
• Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase InhibitorsTerminatedNCT01225172Phase 2Results posted
• Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast CancerCompletedNCT00971945Phase 2Results posted
• Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast CancerCompletedNCT00767520Phase 2Results posted
• Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase InhibitorCompletedNCT00754325Phase 2Results posted
• Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or MetastaticCompletedNCT00696072Phase 2Results posted
• First Line Therapy for Patients With Metastatic Breast CancerTerminatedNCT00456846Phase 2Results posted
• Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast CancerCompletedNCT00455533Phase 2Results posted
• Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast CancerCompletedNCT00452673Phase 1Results posted
• Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast CancerCompletedNCT00394251Phase 2Results posted
• ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast CancerCompletedNCT00394082Phase 2Results posted
• Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast CancerCompletedNCT00371345Phase 2Results posted
• A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast CancerCompletedNCT00371254Phase 2Results posted
• Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast CancerTerminatedNCT00281528Phase 2Results posted
• Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast CancerCompletedNCT00274456Phase 2Results posted
• A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast CancerTerminatedNCT00140140Phase 1/2Results posted
• Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast CancerCompletedNCT00093145Phase 2Results posted
• A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has SpreadCompletedNCT04132817Phase 1
• Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical PracticeTerminatedNCT02655159
• Abraxane in Treatment of Metastatic Breast CancerCompletedNCT02555696
• Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line MonochemotherapyCompletedNCT02403869
• Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast CancerCompletedNCT02309177Phase 1
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
• Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast CancerCompletedNCT01068704Phase 2
• Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast CancerCompletedNCT01023204Phase 2
• Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab TherapyCompletedNCT00803556Phase 1
• Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast CancerCompletedNCT00788333Phase 1/2
• Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast CancerTerminatedNCT00780000Phase 2
• Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed HerceptinCompletedNCT00773344Phase 1/2
• ABI-008 Trial in Patients With Metastatic Breast CancerTerminatedNCT00531271Phase 1/2
• Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer TumorsTerminatedNCT00511576Phase 1
• Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast CancerWithdrawnNCT00380835Phase 2
• Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast CancerCompletedNCT00107094Phase 1
• Study of MDX-010 in Stage IV Breast CancerCompletedNCT00083278Phase 2
• Study of ABI-007 and Taxol in Patients With Metastatic Breast CancerCompletedNCT00046527Phase 3
• ABI-007 in Taxol Resistant Patients With Metastatic Breast CancerCompletedNCT00046514Phase 2
• A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal TherapyTerminatedNCT00036621Phase 2